RIMEGEPANT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RIMEGEPANT (RIMEGEPANT).
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. It blocks CGRP-mediated vasodilation and pain transmission in the trigeminovascular system.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C9. |
| Excretion | Rimegepant is eliminated primarily via hepatic metabolism (CYP3A4 and CYP2C9) and biliary/fecal excretion. Approximately 78% of the administered dose is recovered in feces (77% as parent drug and 1% as metabolites), and 24% is recovered in urine (0.5% as parent drug and 23.5% as metabolites). |
| Half-life | The terminal elimination half-life of rimegepant is approximately 11 hours. This supports once-daily oral dosing for acute migraine treatment, with steady-state reached within 7 days. |
| Protein binding | Rimegepant is approximately 96% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution is approximately 120 L (1.7 L/kg for a 70 kg individual), indicating extensive tissue distribution beyond plasma water. |
| Bioavailability | Oral bioavailability is approximately 64% (range 53-76%) under fasting conditions. Administration with a high-fat meal reduces Cmax and AUC by approximately 48% and 32%, respectively, but does not significantly affect efficacy. |
| Onset of Action | Oral administration: Onset of pain relief occurs as early as 60 minutes in some patients, with significant improvement over placebo observed at 2 hours post-dose. |
| Duration of Action | The duration of therapeutic action for acute migraine is up to 48 hours, based on sustained pain freedom and freedom from most bothersome symptom endpoints. Single oral dose provides relief for the duration of a typical migraine attack. |
75 mg orally as needed, maximum 75 mg in 24 hours; or 75 mg orally every other day for prevention.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No adjustment required for mild to moderate impairment (eGFR ≥30 mL/min). For severe impairment (eGFR <30 mL/min) or ESRD, not recommended (no data). |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose to 75 mg every other day. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established; no approved pediatric dosing. |
| Geriatric use | No specific dose adjustment; consider age-related renal/hepatic function; same adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RIMEGEPANT (RIMEGEPANT).
| Breastfeeding | Not recommended during breastfeeding due to potential for adverse effects in infant; M/P ratio unknown. |
| Teratogenic Risk | No adequate studies in pregnant women; animal studies show no evidence of harm at clinically relevant doses. Caution in first trimester due to unknown effects on neural tube closure. |
| Fetal Monitoring | Monitor for maternal hepatic function and blood pressure; fetal ultrasound for growth and development if used during pregnancy. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) is contraindicated.","History of hypersensitivity to rimegepant or any of its components."]
| Precautions | ["Serious hypersensitivity reactions (including anaphylaxis, dyspnea, and rash) have been reported; discontinue if hypersensitivity occurs.","Avoid concurrent use with strong CYP3A4 inducers or inhibitors as they may alter rimegepant exposure.","Potential for decreased efficacy with strong CYP3A4 inducers."] |
Loading safety data…
| Fertility Effects | No known effects on human fertility; animal studies show no impairment at clinically relevant doses. |